Serum IGF-1 in patients with rheumatoid arthritis: correlation with disease activity

Hanna Lee¹, Young Sun Suh², Sang-Hi Lee¹, Yun-Hong Cheon¹, Mingyo Kim¹, Hae Sook Noh³ and Hyun-Ok Kim²*

Abstract

Objective: Insulin-like growth factor (IGF)-1 participates in modulating immunity and inflammation. Its bioactivity is controlled by six IGF-binding proteins (IGFBP-1 to IGFBP-6). In particular, the IGFBP-3 level is reportedly linked to the disease activity of rheumatoid arthritis (RA), consistent with our previous study. Therefore, the present study aimed to reproduce the previous results.

Results: The serum IGFBP-3 level was not significantly different among the three groups according to disease activity based on the DAS28-ESR/CRP (p > 0.05) but was significantly different between the low- and high-disease-activity groups based on the DAS28-CRP (p = 0.036). Meanwhile, the interleukin-6 (IL-6) level moderately correlated with DAS28-CRP (Spearman’s rho = 0.583, p < 0.001).

Keywords: Rheumatoid arthritis, Disease activity, Insulin-like growth factor-1, Insulin-like growth factor binding protein-3

Introduction

Rheumatoid arthritis (RA) is a common chronic inflammatory and autoimmune disease primarily involving the synovial membranes and articular structures of multiple joints, although with unknown etiology [1].

In regulating inflammation and immunity, a vast network of interacting cells and cytokines is required. The endocrine system also participates in various ways in immune regulation through the actions of growth hormones, especially insulin-like growth factor-1 (IGF-1) [2]. IGF-1 promotes the growth and differentiation of the bone and cartilage tissue and participates in regulating immunity and inflammation [3].

IGF-1 has a fundamental role in both prenatal and postnatal development; it binds to the IGF-1 receptor (IGF-1R) to exert all of its known physiologic effects, which are modulated by multiple IGF-binding proteins (IGFBPs) [4]. Currently, six IGFBP types have been identified (IGFBP-1 to IGFBP-6). Among them, IGFBP-3 is the most important, and it carries up to 75 to 90% of circulating IGF-1 and regulates the action of IGF-1 through interaction with the receptor IGF-1R [5]. Several rheumatic diseases, such as osteoarthritis, diffuse idiopathic skeletal hyperostosis, and RA, exhibit abnormalities in the serum and/or synovial fluid levels of growth hormone (GH)/IGF-1 [3, 6, 7]. However, the mechanism on how the IGF system is involved in RA disease activity remains poorly known. Our previous study showed that the IGFBP-3 levels were significantly higher in patients with RA, particularly in those with active RA. Furthermore, the IGFBP-3 levels in the serum and synovial fluid had a significantly positive correlation with the erythrocyte sedimentation rate (ESR) and CRP level that highly correlate with RA disease activity in patients with RA [8].

However, the serum concentration of IGFBP-3 either increases [9, 10] or decreases [11], depending on the
results presented in the previous studies, presumably because of differences in the patient’s age or RA activity level.

Therefore, this study aimed to determine the relationship between the IGFBP-3 system and the disease activity of RA and to reproduce the results of our previous study.

Main text
Material and methods
Patients
From January 2014 to June 2014, we included 80 patients diagnosed with RA (62 females, 18 males) in the outpatient department of the Division of Rheumatology in Gyeongsang National University Hospital located in Jinju, Korea. RA diagnosis was based on the 1987 and/or 2010 American College of Rheumatology criteria/European League against Rheumatism collaboration. All patients were treated by the same group of rheumatologists.

A serum sample was obtained from each patient and was stored at −80 °C until analysis. The institutional review board of the abovementioned hospital approved this study (2013-03-006), which conformed to the Declaration of Helsinki II. All patients were informed and gave their written consent.

Clinical data and measurement of inflammatory markers
All patients were followed up to obtain the following clinical data: age, sex, smoking history, ESR, C-reactive protein (CRP), rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibody, and the disease activity score in 28 joints (DAS28) with ESR/CRP (DAS28-ESR/CRP).

DAS28 was calculated as described in this link: http://www.4s-dawn.com/DAS28/. We then classified the patients into low-, moderate-, and high-disease-activity groups according to the DAS28 results (low, < 3.2; moderate, 3.2–5.1; high > 5.1) [12].

Measurement of IGF-1 and IGFBP3
Serum IGF-1 and IGFBP-3 levels were measured by enzyme-linked immunosorbent assay (ELISA) using a commercial kit (R&D systems) according to the manufacturer’s instructions.

Statistical analysis
All statistical data were analyzed using SPSS 21.0 (SPSS Inc., Chicago, IL, USA). In addition, p < 0.05 indicated a significant difference. Using the Kruskal–Wallis test, we compared the serum cytokine levels among the patient groups. Furthermore, the correlations of serum cytokine levels with the DAS28-ESR/CRP were investigated by Spearman’s rank correlation analysis.

Results
Patient baseline characteristics
Table 1 summarizes the baseline clinical and laboratory characteristics of the 80 study patients. Their mean age was 59.1 ± 9.6 years, and 62 (77.5%) of them were female. Furthermore, 69 (86.3%) were RF positive, and 67 (85.9%) were anti-CCP antibody positive.

Relationship between serum cytokines and disease activity based on DAS28 ESR
According to the DAS28-ESR results, 20, 21, and 39 patients were categorized into the low-, moderate-, and high-disease-activity groups, respectively. Among these three groups, no significant difference was observed in terms of age and gender (p > 0.05) and the IGFBP-3 level (Table 2, p > 0.05). In addition, no significant difference was found between the IGFBP-3 or IGF-1 level and ESR (p > 0.05). However, the IL (interleukin)-6 level was significantly different among the three groups (Table 2, p < 0.001) but moderately correlated with the DAS28-ESR (Spearman’s rho = 0.602, p < 0.001).

Relationship between serum cytokines and disease activity based on DAS28-CRP
According to the DAS28-CRP results, 35, 23, and 22 patients were categorized into the low-, moderate-, and high-disease-activity groups, respectively. Among these groups, no significant difference was found in terms of age and gender (> 0.05). However, the IL-6 level was significantly different among the three groups (Table 2, p < 0.001) and moderately correlated with the DAS28-CRP (Spearman’s rho = 0.602, p < 0.001).

Table 1  Baseline characteristics of the study patients

| Characteristics         | Patients (n = 80) |
|-------------------------|------------------|
| Age, years              | 59.1 ± 9.6       |
| Gender, male/female     | 18/62            |
| Rheumatoid factor (positive) | 69 (86.3) |
| Anti-CCP antibody (positive) | 67 (83.8) |
| ESR, mm/h               | 51.8 ± 32.3      |
| CRP, mg/L               | 15.4 ± 22.9      |
| Pain (VAS), mm          | 3.5 ± 2.7        |
| Tender joint count      | 4.8 ± 5.2        |
| Swollen joint count     | 5.7 ± 6.0        |
| DAS28-ESR               | 4.7 ± 1.9        |
| DAS28-CRP               | 3.8 ± 1.8        |
| IGF-1, pg/ml            | 286.2 ± 264.5    |
| IGFBP-3, pg/ml          | 5581.1 ± 1172.5  |
| TNF-α, pg/ml            | 38.2 ± 113.75    |
| IL-1, pg/ml             | 6.4 ± 16.40      |
| IL-6, pg/ml             | 17.2 ± 30.97     |

Numerical data are presented as mean ± one standard deviation, or number of patients with percentages in parentheses, as appropriate.
age and gender ($p > 0.05$), the IGFBP-3 level (Table 3, $p > 0.05$), and the IL-6 level (Table 3, $p < 0.001$). However, the IGF-1 level was significantly different between the low- and high-disease-activity groups ($p = 0.036$). Meanwhile, no significant difference was found between the IGFBP-3 or IGF-1 level and CRP ($p > 0.05$). Additionally, the IL-6 level moderately correlated with DAS28-CRP (Spearman’s rho $= 0.583$, $p < 0.001$).

**Discussion**

As a lymphohemopoietic cytokine, IGF-1 has profound positive effects on immune function [13]. IGF-1 binds to T and B cells [14] and induces anti-CD3-stimulated T cell proliferation and chemotaxis [13, 15]. It also activates T cell Akt, thereby enhancing lymphocyte survival [16]. Recently, IGF-1 reportedly prevents cord blood T cells from spontaneous apoptosis when cultured in a serum-free medium. Furthermore, IGF-1 significantly inhibits the spontaneous apoptosis of all the subsets of cord blood T cells [17]. Hence, IGF-1 influences the onset of inflammatory diseases, thereby may be a useful target. The abundance and profile of IGFBPs serve as important determinants of signaling by influencing IGF availability for receptor binding [13]. Thus, our group previously confirmed the correlation between IGFBP-3, which is essential in IGF-1 activity, and RA activity. Previously, we showed that the IGFBP-3 levels in the serum and synovial fluid were significantly higher in patients with RA and had a significantly positive correlation with the ESR and CRP levels that highly correlate with RA disease activity in these patients [8]. However, ESR and CRP have limitations in reflecting clinical symptoms such as joint swelling or tenderness when evaluating disease activity of patients with RA. Therefore, in the present study,

### Table 2
Comparison of serum cytokines among patient groups according to disease activity based on DAS28-ESR

| Serum cytokines | Low disease activity ($n = 20$) | Moderate disease activity ($n = 21$) | High disease activity ($n = 39$) | $p$ value |
|-----------------|-------------------------------|----------------------------------|-------------------------------|-----------|
| IGF-1 (pg/ml)   | 166.200 (116.305, 307.555)    | 153.070 (100.038, 327.442)       | 229.920 (142.760, 423.772)    | 0.314     |
| IGFBP-3 (pg/ml) | 5359.140 (5001.525, 5901.715) | 5818.650 (5105.312, 6321.658)   | 5732.090 (5277.685, 6779.132) | 0.175     |
| TNF-α (pg/ml)   | 6.545 (3.412, 13.093)         | 7.661 (4.109, 12.989)           | 9.680 (4.736, 13.789)         | 0.650     |
| IL-1 (pg/ml)    | 2.189 (1.630, 2.939)          | 2.262 (2.066, 3.120)            | 2.557 (2.139, 3.092)          | 0.270     |
| IL-6 (pg/ml)    | 1.819 (0.809, 2.588)          | 4.569 (2.871, 11.973)           | 13.399 (3.720, 36.984)        | $< 0.001$ |

| Numeral data are presented as mean ± one standard deviation, or number of patients with percentages in parentheses, as appropriate |

DAS28-ESR disease activity score in 28 joints with estimated sedimentation rate, IGF insulin-like growth factor, IGFBP insulin-like factor binding protein, IL interleukin, TNF-α tumor necrosis factor alpha

### Table 3
Comparison of serum cytokines among patient groups according to disease activity based on DAS28-CRP

| Serum cytokines | Low disease activity ($n = 35$) | Moderate disease activity ($n = 23$) | High disease activity ($n = 22$) | $p$ value |
|-----------------|-------------------------------|----------------------------------|-------------------------------|-----------|
| IGF-1 (pg/ml)   | 153.070 (98.480, 311.705)     | 221.250 (110.138, 470.130)       | 245.990 (191.280, 401.430)    | 0.036     |
| IGFBP-3 (pg/ml) | 5563.720 (5068.687, 6101.353) | 5732.090 (5286.497, 6142.102)   | 5706.875 (5227.440, 6868.740) | 0.587     |
| TNF-α (pg/ml)   | 5.989 (2.821, 13.163)         | 7.800 (4.736, 12.814)           | 10.098 (4.945, 13.580)        | 0.425     |
| IL-1 (pg/ml)    | 2.189 (1.844, 2.951)          | 2.410 (2.016, 3.074)            | 2.557 (2.167, 3.086)          | 0.167     |
| IL-6 (pg/ml)    | 2.547 (1.739, 4.286)          | 4.447 (3.578, 15.119)           | 33.513 (6.752, 58.346)        | $< 0.001$ |

| Numeral data are presented as mean ± one standard deviation, or number of patients with percentages in parentheses as appropriate |

DAS28-CRP disease activity score in 28 joints with C-reactive protein, IGF insulin-like growth factor, IGFBP insulin-like factor binding protein, IL interleukin, TNF-α tumor necrosis factor alpha
we investigated patient’s disease activity and IGFBP-3 levels by using DAS28-ESR/CRP, which is used to measure disease activity in patients with RA. Contrary to our hypothesis, DAS28-ESR/CRP and IGFBP-3 showed no significant association. Unlike the previous results, IGFBP3 had no correlation with ESR and CRP. Thus, in this study, we investigated the correlation between DAS28-ESR/CRP and IGF-1, which is the major ligand for IGFBP-3, in patients with RA. Interestingly, IGF-1 reflects a statistically significant difference between the high-disease-activity and low-disease-activity groups of DAS28-CRP. However, IGF-1 had no correlation with ESR and CRP. Moreover, IL-6 was statistically significant in reflecting the RA activity. IL-6 is one of the cytokines that play an important role in RA pathogenesis. In an animal study, IL-6 functioned as an antiapoptotic cytokine that prevents T cell apoptosis [18]. IL-6 promotes B cell differentiation into the plasma cell and also influences T cell development by stimulating T cell proliferation and differentiation into Th-17 cells, which produce IL-17 [19].

In the current study, IGF-1 and IL-6 reflected RA activity through the use of DAS28-CRP, but the results of this study alone limitedly explained the interaction between IGF-1 and IL-6. Nevertheless, on the basis of the results of existing research, our results allow to hypothesize that IGF-1 may prevent T cell apoptosis and contribute to the antiapoptotic effect in part via IL-6. Further investigation is required to elucidate the correlation of IL-6 and IGF-1 with the RA activity.

Limitations
Our study has several possible limitations. First, we had no control group to be compared with our patients with RA. Second, the evaluation method of RA disease activity is inadequate. We only used the DAS28-ESR/CRP to evaluate the RA disease activity. According to a recent study [20], clinical disease activity index and simplified disease activity index showed more congruous classification of disease activity than DAS28-ESR across different populations. Therefore, further study is necessary to confirm our results with the evaluation of these indices.

Abbreviations
RA: Rheumatoid arthritis; IGF: Insulin-like growth factor; IGFBP: Insulin-like growth factor binding protein.

Acknowledgements
Not applicable.

Authors’ contributions
L.H. and S.Y.S. and K.H.-O. designed the experiments and wrote the manuscript. N.H.S. and K.M. performed the experiments. L.H. and S.Y.S. and K.M. performed the analyzed data. L.S.I. and C.Y.-H. revised the manuscript. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations
Ethics approval and consent to participate
Approved by Gyeongsang National Changwon Hospital Institutional Review Board with the written informed consent from participants.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine and Hospital, Jinju 52727, Korea. 2 Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine and Changwon Hospital, Changwon 51427, Korea. 3 Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine and Institute of Health Science, Gyeongsang National University Hospital, Jinju 52727, Korea.

Received: 9 January 2022   Accepted: 15 March 2022
Published online: 05 April 2022

References
1. Lu MC, Yu CL, Chen HC, Yu HC, Huang HB, Lai NS. Increased miR-223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin-like growth factor-1-mediated interleukin-10 production. Clin Exp Immunol. 2014;177:641–51.
2. Heemskerk VH, Daemen MA, Buurman WA. Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Cytokine Growth Factor Rev. 1999;10:S–14.
3. Matsumoto T, Tsurumoto T. Inappropriate serum levels of IGF-1 and IGFBP-3 in patients with rheumatoid arthritis. Rheumatology (Oxford). 2002;41:352–3.
4. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol. 2004;24:435–44.
5. Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 2009;30:417–37.
6. Denko CW, Boja B, Moskowitz RW. Growth factors, insulin-like growth factor-1 and growth hormone, in synovial fluid and serum of patients with rheumatic disorders. Osteoarthritis Cartilage. 1996;4:245–9.
7. Denko CW,Malemud CJ. Role of the growth hormone/insulin-like growth factor-1 paracrine axis in rheumatic diseases. Semin Arthritis Rheum. 2005;35:24–34.
8. Lee HS, Woo SJ, Koh HW, et al. Regulation of apoptosis and inflammatory responses by insulin-like growth factor binding protein 3 in fibroblast-like synoviocytes and experimental animal models of rheumatoid arthritis. Arthritis Rheumatol. 2014;66:863–73.
9. Fernihough JK, Billingham ME, Cwyfan-Hughes S, Holly JM. Local disruption of the insulin-like growth factor system in the arthritic joint. Arthritis Rheum. 1996;39:1556–65.
10. Matsumoto T, Tsurumoto T. Inappropriate serum levels of IGF-1 and IGFBP-3 in patients with rheumatoid arthritis. Rheumatology (Oxford). 2002;41:352–3.
11. Bostrom EA, Svensson M, Andersson S, Jonsson IM, Ekwall AK, Eiser T, et al. Resistin and insulin/insulin-like growth factor signaling in rheumatoid arthritis. Arthritis Rheum. 2011;63:2894–904.
12. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. 2001;44:2009–17.
13. Tu W, Cheung PT, Lau YL. IGF-1 increases interferon-gamma and IL-6 mRNA expression and protein production in neonatal mononuclear cells. Pediatr Res. 1999;46:748–54.
14. Terry JS. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune disease? Pharmacol Rev. 2010;62:199–236.
15. Tapson VF, Boni-Schnetzler M, Pilch PF, Center DM, Berman JS. Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor-I in vitro. J Clin Invest. 1988;82:950–7.
16. Walsh PT, Smith LM, O’Connor R. Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes. Immunology. 2002;107:461–71.
17. Tu W, Cheung PT, Lau YL. Insulin-like growth factor I promotes cord blood T cell maturation and inhibits its spontaneous and phytohemagglutinin-induced apoptosis through different mechanisms. J Immunol. 2000;165:1331–6.
18. Teague TK, Marrack P, Kappler JW, Vella AT. IL-6 rescues resting mouse T cells from apoptosis. J Immunol. 1997;158:5791–6.
19. Sirirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2010;2:247–56.
20. Canhão H, Rodrigues AM, Gregório MJ, Dias SS, Melo Gomes JA, Santos MJ, et al. Common evaluations of disease activity in rheumatoid arthritis reach discordant classification across different populations. Front Med (Lausanne). 2018;5:40.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.